bronchiol
obliteran
syndrom
bo
eventu
occur
major
lung
transplant
recipi
surviv
beyond
year
greatli
impair
qualiti
life
directli
indirectli
major
caus
delay
allograft
dysfunct
recipi
death
number
associ
event
condit
strongli
associ
risk
develop
bo
includ
acut
reject
gastroesophag
refl
ux
infect
autoimmun
reaction
occur
set
alloimmun
respons
lung
allograft
recipi
given
intens
immunosuppress
prevent
allograft
reject
term
chronic
lung
allograft
dysfunct
clad
increasingli
use
refer
recipi
late
allograft
dysfunct
meet
spirometr
criteria
diagnosi
bo
clinician
recogn
dysfunct
occur
varieti
reason
bo
recent
identifi
ed
entiti
restrict
allograft
syndrom
recogn
rel
distinct
phenotyp
clad
featur
differenti
classic
obstruct
bo
number
entiti
also
signifi
cantli
affect
allograft
function
must
also
consid
signific
allograft
dysfunct
encount
follow
lung
transplant
late
lung
allograft
dysfunct
progress
loss
function
graft
loss
origin
describ
heartlung
transplant
recipi
histopatholog
postmortem
examin
lung
reveal
lesion
constrict
bronchiol
airway
fi
brosi
lumin
obliter
design
oblit
bronchiol
ob
late
declin
allograft
function
follow
recoveri
stabil
lung
function
initi
lung
implant
increasingli
encount
lung
transplant
perform
late
consensu
document
suggest
term
bronchiol
obliteran
syndrom
bo
could
use
design
syndrom
persist
loss
function
declin
fev
could
explain
potenti
revers
complic
acut
reject
infect
publish
clinic
experi
evolv
subsequ
decad
lung
transplant
confi
rmed
patholog
fi
nding
usual
correl
persist
declin
posttranspl
fev
consist
clinic
diagnosi
bo
presenc
lesion
ob
threshold
declin
fev
pattern
airfl
ow
obstruct
establish
baselin
chosen
previou
consensu
document
appropri
surrog
marker
ob
due
strong
associ
ob
late
chronic
allograft
dysfunct
major
consider
led
choos
fev
surrog
marker
rel
diffi
culti
obtain
adequ
diagnost
tissu
via
transbronchi
lung
biopsi
tblb
plu
desir
avoid
substanti
increas
risk
perform
invas
diagnost
procedur
ie
surgic
lung
biopsi
although
extens
sampl
lung
tissu
could
facilit
confi
dent
diagnosi
may
consid
necessari
certain
situat
chapter
provid
overview
current
concept
pertain
bo
terminolog
use
describ
delay
chronic
allograft
dysfunct
posttranspl
ob
character
progress
obliter
small
airway
accompani
persist
declin
fev
obstruct
spirometr
pattern
essenti
clear
chest
radiograph
lack
altern
diagnosi
explain
persist
declin
lung
function
syndrom
presum
caus
chronic
allograft
reject
term
chronic
lung
allograft
dysfunct
clad
coin
use
refer
allograft
dysfunct
met
criteria
adopt
indic
diagnosi
bo
previous
publish
consensu
statement
design
persist
declin
fev
baselin
posttranspl
fev
present
minimum
week
absenc
confound
condit
surrog
marker
probabl
ob
tabl
stage
system
devis
qualifi
level
fev
declin
correl
fairli
well
sever
allograft
dysfunct
defi
nition
month
requir
elaps
time
transplant
order
diagnosi
bo
made
qualifi
cation
made
help
distinguish
bo
nonbo
acut
andor
subacut
complic
lung
transplant
well
take
account
time
need
establish
baselin
fev
confi
rmed
declin
fev
fev
measur
taken
week
apart
concern
cutoff
valu
fev
best
posttranspl
valu
may
insensit
earli
declin
allograft
function
due
earli
ob
stage
fev
baselin
andor
fef
baselin
ad
stage
system
signifi
potenti
bo
one
problem
scheme
consider
variat
fev
valu
recipi
may
due
time
fl
uctuat
spirometr
measur
caus
variou
posttranspl
complic
prevent
recipi
achiev
graft
function
plateau
reason
stabl
posttranspl
fev
valu
accur
repres
zenith
attain
function
fl
uctuat
consequ
inabl
establish
stabl
posttranspl
lung
function
make
diffi
cult
imposs
identifi
accur
baselin
valu
identifi
cation
surrog
marker
eg
biomark
accur
refl
ect
patholog
airway
andor
parenchym
process
specifi
c
intervent
consid
much
need
consider
number
risk
factor
associ
develop
bo
tabl
bo
wide
perceiv
physiolog
surrog
immunolog
mediat
phenomenon
due
mani
observ
includ
associ
acut
cellular
reject
associ
greater
degre
hla
mismatch
bo
risk
evolv
evid
involv
autoimmun
pathway
interplay
alloimmun
autoimmun
process
lead
allograft
reject
furthermor
lung
histopatholog
patient
bo
show
strike
similar
ob
occur
allogen
bone
marrow
stem
cell
transplant
recipi
well
constrict
bronchiol
patient
connect
tissu
diseas
airway
chang
perceiv
alloimmun
autoimmun
disord
respect
nonetheless
although
bo
frequent
equat
term
chronic
reject
variou
intervent
includ
intensifi
ed
immunosuppress
may
littl
effect
progress
loss
allograft
function
usual
observ
lung
transplant
recipi
develop
bo
howev
patient
signifi
cant
clinic
respons
altern
immunomodulatori
therapi
total
lymphoid
irradi
extracorpor
photopheresi
although
respons
gener
consist
stabil
decreas
tempo
lung
function
loss
time
unlik
improv
lung
function
see
chap
addit
alloimmun
andor
autoimmun
phenomena
associ
bo
variou
nonimmun
mechan
implic
play
role
bo
pathogenesi
although
often
refer
nonimmun
eventsphenomena
like
trigger
potenti
innat
immun
respons
may
also
trigger
intensifi
alloimmun
autoimmun
respons
mechan
includ
injuri
caus
primari
graft
dysfunct
pgd
gastroesophag
refl
ux
ger
infect
caus
virus
bacteria
fungi
like
involv
allograft
injuri
combin
trigger
innat
immun
respons
may
also
trigger
potenti
alloimmuneadapt
immun
respons
pgd
affect
lung
transplant
lead
caus
earli
morbid
mortal
repres
form
acut
lung
injuri
consid
occur
larg
consequ
period
ischemia
reperfus
donor
lung
procur
implant
recipi
although
number
studi
consist
link
pgd
bo
recent
studi
support
link
pgd
develop
bo
daud
et
al
found
convinc
associ
pgd
grade
increas
risk
develop
bo
stage
use
intern
societi
heart
lung
transplant
ishlt
consensu
defi
nition
pgd
recent
analysi
outcom
group
identifi
ed
direct
relationship
pgd
sever
h
posttranspl
increas
risk
bo
sever
grade
pgd
grade
three
time
point
associ
highest
risk
develop
bo
rr
grade
pgd
h
presenc
signifi
cant
ger
ger
increas
frequencysever
consid
normal
increas
risk
refl
uxat
aspir
lower
respiratori
tract
link
subacut
chronic
lung
allograft
dysfunct
multipl
studi
report
high
preval
abnorm
degre
ger
among
patient
advanc
lung
diseas
patient
refer
lung
transplant
approxim
patient
undergo
transplant
evalu
evid
signifi
cant
ger
acid
refl
ux
may
worsen
follow
transplant
gastroparesi
esophag
dysmotil
may
also
present
increas
risk
refl
ux
microaspir
neg
correl
found
increas
sever
acid
refl
ux
measur
ph
studi
posttranspl
fev
presenc
nonacid
refl
ux
measur
imped
test
report
increas
risk
bo
nearli
threefold
refl
uxe
bile
acid
bal
fl
uid
found
increas
crosssect
studi
patient
bo
ger
associ
aspir
bile
acid
bile
acid
detect
bal
link
bo
signifi
cantli
increas
risk
bo
onset
poor
respons
azithromycin
therapi
recent
studi
anim
model
lung
transplant
suggest
gastric
aspir
might
enhanc
allorecognit
promot
lung
allograft
reject
ger
link
collagen
v
sensit
bo
transplant
recipi
infect
caus
virus
bacteria
fungi
link
risk
develop
bo
see
chap
larg
number
studi
link
pulmonari
cmv
infect
subsequ
develop
bo
andor
diminish
posttranspl
surviv
prophylact
preemptiv
strategi
preventtreat
cmv
infect
signifi
cantli
reduc
incid
cmv
diseas
lung
transplant
recipi
retrospect
studi
periop
ganciclovir
prophylaxi
suggest
prevent
cmv
diseas
may
delay
onset
bo
howev
recent
publish
prospect
singlecent
studi
report
incid
cmv
pneumon
within
month
transplant
cohort
recipi
despit
shortcours
prophylaxi
given
highrisk
recipi
investig
observ
cmv
pneumon
associ
signifi
cantli
increas
risk
bo
hr
diminish
surviv
hr
interestingli
prospect
random
trial
examin
effect
vs
month
posttranspl
valganciclovir
prophylaxi
dr
recipi
show
prophylaxi
strategi
signifi
cantli
diminish
incid
cmv
infect
vs
cmv
diseas
vs
diseas
sever
without
signifi
cant
differ
rate
acut
reject
opportunist
infect
cmv
ganciclovirresist
mutat
advers
event
howev
remain
unclear
whether
prolong
prophylaxi
reduc
risk
bo
infect
beta
herp
virus
may
also
caus
seriou
complic
noncmv
virus
includ
epsteinbarr
viru
ebv
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
human
herp
virus
prospect
cohort
studi
lung
transplant
recipi
link
repetit
detect
ebv
dna
peripher
blood
develop
bo
infect
associ
bo
infect
communityacquir
respiratori
virus
carv
asymptomat
caus
mild
symptom
caus
signifi
cant
respiratori
tract
diseas
lead
acut
respiratori
insuffi
cienci
death
recoveri
carv
infl
uenza
b
respiratori
syncyti
viru
parainfl
uenza
virus
rhinovirus
enterovirus
adenovirus
human
metapneumoviru
human
coronaviru
human
bocaviru
infect
suspici
carv
lung
transplant
recipi
rang
retrospect
well
recent
prospect
investig
link
carv
infect
bo
risk
posttranspl
bacteri
infect
exceedingli
common
recipi
prior
septic
lung
diseas
cf
noncf
bronchiectasi
lead
caus
death
recipi
establish
bo
botha
et
al
report
de
novo
allograft
colon
pseudomona
aeruginosa
strongli
associ
develop
bo
within
year
transplant
colon
vs
noncolon
vo
et
al
report
persist
pseudomona
colon
even
greater
risk
bo
de
novo
colon
gottlieb
et
al
found
persist
allograft
pseudomona
colon
cohort
patient
cf
signifi
cantli
increas
preval
bo
addit
vo
et
al
report
bal
bile
acid
level
neutrophil
level
correl
significantli
pseudomona
colon
suggest
presenc
abnorm
ger
microaspir
lead
persist
colon
pseudomona
invas
fungal
infect
import
caus
morbid
mortal
lung
transplant
recipi
valentin
et
al
report
diagnosi
fungal
pneumonia
pneumon
cohort
recipi
independ
predictor
bo
hazard
ratio
ci
earli
day
posttranspl
ci
late
year
fungal
pneumonia
multivari
analysi
anoth
studi
recipi
report
aspergillu
colon
independ
associ
multivari
cox
regress
analysi
subsequ
develop
bo
hr
ci
bosassoci
mortal
hr
ci
addit
recipi
new
persist
aspergillu
colon
develop
bo
increas
risk
progress
stage
bo
death
recent
observ
also
suggest
environment
exposur
lead
airway
injuri
obliter
nontranspl
patient
higher
ambient
level
pollut
recent
link
bo
lung
transplant
recipi
addit
airway
ischemia
caus
disrupt
bronchial
circul
also
suggest
potenti
caus
bo
establish
ob
display
variabl
evid
infl
ammat
combin
evid
heighten
innat
immun
respons
alloimmun
reaction
autoimmun
fi
broprolifer
airway
obliter
lead
allograft
airway
remodel
loss
function
ob
like
repres
fi
nal
common
endpoint
allograft
bronchiolar
injuri
precipit
andor
driven
varieti
insult
mechan
past
decad
becom
increasingli
recogn
mani
recipi
declin
lung
function
consist
fev
criteria
bo
respond
certain
intervent
see
chap
tabl
macrolid
neomacrolid
azalid
azithromycin
possess
antiinfl
ammatori
effect
inhibit
product
neutrophil
recruit
suppress
bronchial
infl
ammat
prevent
modul
airway
damag
number
respiratori
disord
observ
mani
center
indic
substanti
number
patient
develop
clinic
bo
respond
azithromycin
may
lung
function
stabil
signifi
cantli
improv
see
chap
patient
may
longer
meet
fev
criteria
bo
respond
drug
azithromycin
appear
capabl
diminish
risk
graft
loss
recipi
death
given
patient
establish
bo
addit
recent
publish
random
prospect
placebocontrol
clinic
trial
conduct
vo
et
al
suggest
prophylact
administr
azithromycin
initi
shortli
transplant
signifi
cantli
decreas
risk
develop
bo
although
signifi
cant
impact
surviv
shown
rel
brief
evalu
period
mention
abnorm
ger
highli
preval
patient
advanc
lung
diseas
lung
transplant
recipi
preval
may
increas
posttranspl
notabl
abnorm
acid
ger
strongli
link
risk
bo
see
chap
howev
pharmacolog
therapi
protonpump
inhibitor
ppi
although
therapi
increas
ph
gastric
secret
reliev
symptom
may
littl
effect
ger
inde
ppi
therapi
may
neglig
effect
nonacid
refl
ux
may
contain
bile
acid
injuri
lung
pharmacolog
suppress
gastric
acid
secret
may
signifi
cantli
suppress
abnorm
ger
especi
weakli
acid
nonacid
refl
ux
microaspir
gastric
fundopl
investig
consider
degre
mean
prevent
lung
transplant
complic
treatment
bo
refl
ux
appear
present
one
case
seri
suggest
may
prevent
appear
bo
prevent
progress
abnorm
ger
diagnos
patient
develop
bo
addit
improv
fev
observ
azithromycin
therapi
fundopl
report
lead
improv
lung
function
patient
revert
bo
stage
summari
becom
clear
lung
function
declin
consist
diagnosi
bo
stabil
patient
lead
sustain
progress
deterior
allograft
function
graft
loss
allograft
function
declin
consist
onset
bo
may
respond
azithromycin
therapi
antirefl
ux
surgeri
spirometr
criteria
bo
longer
met
due
improv
fev
clinic
statu
howev
treatment
bo
intensifi
ed
immunosuppress
modal
remain
rel
ineffect
date
research
basic
pathogenet
mechan
prevent
strategi
treatment
intervent
greatli
need
seem
logic
use
term
clad
indic
late
delay
signifi
cant
declin
lung
function
due
evolv
ob
well
caus
allograft
dysfunct
chronic
set
howev
recogn
clad
increasingli
use
indic
declin
fev
appear
meet
criteria
bo
may
necessarili
caus
chronic
reject
mediat
classic
alloimmun
respons
see
chap
addit
number
process
may
oper
simultan
contribut
declin
allograft
function
exampl
presenc
signifi
cant
anastomot
dysfunct
combin
ob
abil
identifi
characterist
identifi
subset
lung
transplant
recipi
allograft
function
declin
meet
criteria
bo
may
specifi
c
diseas
mechan
specifi
c
trigger
event
pathway
characterist
predict
benefi
cial
respons
specifi
c
treatment
intervent
aid
effort
provid
specifi
c
treatment
make
key
manag
decis
concern
specifi
c
therapi
treat
bo
caus
clad
recent
describ
characterist
distinguish
typic
bosob
tabl
sato
et
al
identifi
ed
recipi
transplant
develop
clinic
pictur
consist
clad
defi
ned
irrevers
declin
fev
baselin
diagnos
clad
display
evid
restrict
irrevers
declin
total
lung
capac
tlc
baselin
associ
thorac
imag
hrct
chang
consist
interstiti
lung
diseas
ild
peripher
parenchym
lung
fi
brosi
constel
fi
nding
term
restrict
allograft
syndrom
ra
surviv
wors
patient
ra
vs
patient
typic
bo
vs
day
p
two
group
also
describ
subset
bo
patient
featur
restrict
via
pulmonari
function
test
verleden
et
al
diagnos
clad
recipi
found
patient
restrict
chang
pulmonari
function
test
recipi
persist
parenchym
infi
ltrate
hrct
multivari
analysi
show
restrict
pattern
pulmonari
function
test
declin
tlc
declin
fev
fvc
restrict
fev
fvc
ratio
associ
wors
surviv
woodrow
et
al
also
identifi
ed
substanti
number
recipi
clad
met
fev
criterion
bo
evid
restrict
via
spirometr
test
tlc
data
report
show
forc
vital
capac
declin
baselin
howev
preval
parenchym
infi
ltrate
hrct
similar
restrict
vs
obstruct
group
met
bo
criteria
surviv
differ
group
recent
analysi
recipi
cohort
develop
bo
sato
et
al
shown
detect
diffus
alveolar
damag
dad
lung
biopsi
specimen
may
import
implic
obstruct
bo
ra
report
dad
seen
least
tblb
recipi
earli
dad
month
posttranspl
associ
significantli
increas
mortal
risk
also
found
bilater
lung
recipi
adequ
pulmonari
function
test
distinguish
ra
bo
earlier
onset
bo
earli
dad
detect
addit
late
newonset
dad
day
posttranspl
signifi
cant
risk
factor
develop
ra
review
tempor
chang
lung
biopsi
recipi
ra
show
dad
tend
follow
develop
pleuroparenchym
fi
broelastosi
addit
character
subset
patient
show
groundglass
opac
hrct
correl
dad
episod
episod
accompani
declin
lung
function
subsequ
stabil
interv
period
correl
allograft
fi
brosi
exist
distinct
phenotyp
basi
length
time
transplant
bo
develop
tempo
diseas
progress
suggest
literatur
recipi
earlyonset
bo
may
repres
group
patient
prone
rapid
progress
poor
prognosi
median
surviv
recipi
acuteonset
bo
note
vs
month
later
chroniconset
bo
addit
burton
et
al
found
progress
bo
lower
higher
grade
increas
risk
mortal
threefold
rapid
declin
fev
associ
wors
prognosi
brugier
et
al
found
recipi
earlyonset
bo
lower
mean
fev
need
supplement
oxygen
poorer
graft
surviv
lateronset
bo
observ
suggest
patient
earlyonset
bo
repres
subset
recipi
risk
rapid
declin
lung
function
plu
higher
incid
graft
failur
death
compar
patient
lateonset
bo
howev
patient
rapidli
declin
lung
function
associ
bo
relentless
progress
may
stabil
despit
initi
rapid
bo
onset
fev
declin
presenc
signifi
cant
bronchoalveolar
lavag
bal
neutrophilia
often
associ
highresolut
comput
tomograph
hrct
chang
probabl
cellular
bronchiol
patient
fev
declin
meet
criterion
bo
stage
perceiv
repres
variant
bo
individu
like
respond
azithromycin
therapi
fev
may
improv
recipi
longer
meet
spirometr
criteria
bo
inde
revers
occur
respons
azithromycin
pose
issu
term
classifi
entiti
phenotyp
subtyp
bo
criteria
bo
stage
even
eventu
longer
met
due
signifi
cant
therapeut
respons
phenomenon
term
neutrophil
revers
allograft
dysfunct
nrad
suggest
repres
specifi
c
phenotyp
clad
contrast
nrad
patient
meet
bo
criteria
respond
azithromycin
propos
repres
fi
broprolif
bo
phenotyp
nonetheless
distinct
phenotyp
bo
base
upon
specifi
c
risk
factor
paramet
yet
fi
rmli
establish
azithromycinunrespons
individu
may
signifi
cant
variat
underli
histopatholog
chang
respond
azithromycin
data
sato
et
al
verleden
et
al
indic
recipi
ra
may
compris
rel
specifi
c
clad
phenotyp
distinguish
patient
common
bo
pattern
airfl
ow
obstruct
usual
associ
parenchym
infi
ltrate
observ
suggest
hrct
imag
lung
volum
determin
perhap
fvc
fev
fvc
ratio
use
differenti
recipi
ra
phenotyp
typic
obstruct
bo
pattern
spirometr
criteria
onset
bo
met
howev
ob
lesion
may
present
lung
specimen
recipi
develop
allograft
dysfunct
consist
ra
phenotyp
differenti
diagnosi
acut
lung
allograft
dysfunct
includ
surgic
complic
pgd
hyperacut
reject
earli
allograft
dysfunct
occur
outsid
immedi
postop
period
gener
caus
acut
cellular
reject
lymphocyt
bronchiol
infect
entiti
vascular
humor
reject
pleural
effus
empyema
venou
thromboembol
must
consid
similarli
differenti
diagnosi
late
delay
chronic
allograft
dysfunct
must
includ
consider
number
potenti
complic
discuss
chap
recent
observ
discuss
suggest
imag
determin
lung
volum
differenti
graft
dysfunct
caus
ra
classic
obstruct
bo
distinguish
entiti
may
import
decis
make
eg
consid
earli
list
retransplant
ra
progress
unrespons
therapeut
intervent
prognosi
associ
ra
appear
signifi
cantli
wors
associ
obstruct
bo
addit
hrct
imag
combin
bal
differenti
cell
count
identifi
chang
cellular
bronchiol
hrct
bal
neutrophilia
identifi
patient
high
likelihood
nrad
improv
neomacrolid
therapi
knowledg
evolv
syndrom
differ
phenotyp
characterist
advanc
therapi
may
identifi
ed
provid
benefi
specifi
c
subset
clad
may
effi
caci
phenotyp
suggest
delay
allograft
dysfunct
persist
declin
fev
baselin
use
threshold
valu
signifi
like
onset
clad
fev
declin
trigger
consider
variou
entiti
could
caus
declin
graft
function
appropri
diagnost
test
determin
caus
imag
perform
hrct
expiratori
view
may
provid
use
inform
routin
chest
radiograph
bronchoscopi
examin
bronchial
anastomos
perform
bal
endoscop
lung
biopsi
like
provid
use
inform
combin
clinic
present
physic
examin
imag
pulmonari
function
studi
identifi
andor
rule
variou
potenti
caus
clad
criteria
diagnosi
bo
met
variou
risk
factor
associ
bo
consid
appropri
test
perform
determin
like
etiolog
identifi
treatment
like
stabil
possibl
improv
allograft
function
eg
antirefl
ux
surgeri
signifi
cant
ger
evolv
classifi
cation
scheme
fig
need
valid
adopt
would
allow
precis
defi
nition
term
use
describ
delayedonset
allograft
dysfunct
also
convey
complex
clad
set
lower
threshold
investig
fev
declin
chronic
set
may
allow
earlier
diagnosi
intervent
preserv
allograft
function
promot
evolv
concept
distinct
phenotyp
clad
identifi
ed
may
vari
prognos
respons
therapeut
intervent
percept
chronic
allograft
dysfunct
chang
term
ob
bo
clad
chronic
reject
frequent
use
synonym
pertain
allograft
function
due
ob
recogn
term
bo
present
actual
heterogen
entiti
eg
ra
vs
bo
term
clad
may
better
term
use
delay
allograft
dysfunct
clad
caus
varieti
entiti
impact
allograft
function
bo
one
number
rel
distinct
clad
entiti
bo
phenotyp
may
better
identifi
ed
accord
time
onset
posttranspl
rapid
progress
underli
etiolog
eg
associ
ger
azithromycinrespons
respons
therapi
eg
azithromycin
antirefl
ux
surgeri
suggest
new
classifi
cation
system
precis
defi
nition
creat
delay
allograft
dysfunct
ie
clad
suggest
defi
nition
characterist
clad
subcategori
declin
fev
may
due
probabl
cellular
bronchiol
respond
azithromycin
therapi
fev
signifi
cantli
improv
normal
predictor
increas
likelihood
improv
azithromycin
includ
bal
neutrophilia
neutrophil
hrct
chang
consist
bronchiol
treeinbud
opac
peribronchiolar
infi
ltrate
trap
cxr
routin
chest
radiograph
fef
forc
expiratori
fl
ow
rate
forc
vital
capac
fev
forc
expiratori
volum
fvc
forc
vital
capac
hrct
highresolut
comput
tomogram
pft
pulmonari
function
test
tlc
total
lung
capac
